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Objective: To assess the efficacy of lamivudine treatment on hepatitis B e antigenAbstract
(HBeAg) and/or hepatitis B surface antigen (HBsAg) seroconversion, on other
virological and serological markers of response including hepatitis B virus (HBV)
DNA and serum aminotransferases, and the safety of lamivudine treatment in
hepatitis B patients.
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Patients: This phase III open-label study evaluated the virological and biochemi-
cal response to lamivudine in 70 Portuguese patients with HBeAg positive chronic
hepatitis B. Patients were treated with lamivudine 100mg once daily for 12
months.
Methods: Antiviral activity was assessed by measuring alanine aminotransferase
(ALT)/aspartate aminotransferase (AST) levels at all protocol visits, and hepatitis
B serology and HBV DNA were performed at baseline and at month 12 visits.
Evaluation of safety and tolerance was based on clinical adverse events and
laboratory analyses.
Results: The primary endpoint was virological response at month 12, defined as
loss of detectable HBeAg from serum with a reduction of HBV DNA to undetect-
able levels, and this was observed in 19/69 (27.5%) of patients. Almost half of the
patients were HBV DNA negative by this time. Mean ALT values decreased
steadily during treatment and by 12 months 61% of patients had values within the
normal range. HBeAg seroconversion (HBeAg negative, HBeAb positive) was
achieved in 27.9% of patients by 12 months, although all patients remained
HBsAg positive.
Conclusion: Lamivudine was well tolerated and the incidence of adverse events
was similar to those reported in previous studies. Lamivudine treatment resulted
in virological and biochemical improvements in HBeAg positive chronic hepatitis
B patients, with HBeAg seroconversion in one-third of patients.
Hepatitis B virus (HBV) infection constitutes a and profoundly suppresses hepatitis B virus replica-
tion through inhibition of viral DNA synthesis. Pre-major global health problem. Estimates for the year
vious studies have shown that, for patients with2000 by the WHO were for 400 million people
CHB, 1 year of lamivudine therapy resulted in per-worldwide to be chronically infected with HBV.[1]
sistent suppression of HBV DNA, and a significant-Chronic HBV carriers with evidence of active HBV
ly enhanced hepatitis B e antigen (HBeAg) serocon-replication are at highest risk for the development of
version rate with significant reductions in necroin-progressive liver disease.[2,3] Approximately half of
flammatory activity and delayed progression ofadult HBV carriers have evidence of viral replica-
fibrosis compared with placebo.[10-13] Lamivudinetion, and in this group 15–20% may develop cirrho-
treatment was also associated with a significant re-sis within 5 years.[4-7] For patients with HBV-as-
duction in progression to cirrhosis compared withsociated chronic hepatitis and cirrhosis, 5-year sur-
placebo.[9] The aim of the current study was tovival rates as low as 55% have been reported; for
assess the efficacy (HBeAg and hepatitis B surfacepatients with cirrhosis and signs of hepatic insuffi-
antigen [HBsAg] seroconversion and other serologi-ciency, 5-year survival may be as low as 14%.[2,8] In
cal markers of response) and safety of lamivudineaddition, there is a significantly increased incidence
100mg taken once daily for 1 year in 70 Portugueseof hepatocellular carcinoma in patients with chronic
patients with chronic hepatitis B.hepatitis B (CHB).[9]
The goal of antiviral therapy for HBV infection is Patients and Methods
to reduce the risk of progressive liver disease by
providing long-term suppression or eradication of
Study ParticipantsHBV infection. Lamivudine is the first oral antiviral
therapy approved for the treatment of CHB. Patients eligible for enrolment into this open-
Lamivudine is a nucleoside analogue that rapidly label study included males and females 16–70 years
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of age with detectable HBsAg and HBeAg in serum laboratory (Endoclab, Laboratorio de Endocrino-
at the time of screening and detectable HBsAg for at logia e Patologia Clinica, Porto, Portugal). At each
least the previous 6 months, detectable serum HBV visit, a physical examination was carried out and
DNA levels (DNA enzyme immunoassay detection routine haematological and biochemical assays were
system, DiaSorin, Vercelli, Italy) and alanine ami- performed to determine the safety of the treatment.
notransferase (ALT) levels of between 1.3 and 10 Adverse events that had occurred since the previous
times the upper limit of the normal reference range visit were also recorded. The study was not designed
(ULN) at screening. Patients were excluded if they to evaluate compliance with study medication. Viro-
had hepatitis C or D or HIV infection; decompen- logical testing for YMDD variant was not included
sated liver disease (defined by a serum bilirubin in the protocol.
level more than 2.5 times ULN, a prothrombin time The study design was as similar to routine stan-
prolonged by more than 3 seconds, and a serum dard clinical practice as possible, therefore there
albumin level lower than the normal reference range were no specific requirements for liver biopsies;
or a history of ascites, variceal haemorrhage or however, prior biopsy results could be recorded. The
hepatic encephalopathy); or evidence of autoim- disease stage was assessed as follows; (i) inflamma-
mune hepatitis. Patients were also excluded if they tion/activity graded as none, mild, moderate or se-
had received an investigational drug within 30 days vere; (ii) fibrosis (disease stage) evaluated as none,
before enrolment, or were known to require any mild, moderate or severe. Presence or absence of
systemic antiviral therapy, immunomodulators, cirrhosis was also indicated. No specific scale sys-
cytotoxic agents or corticosteroids. Pregnant and tem was used, as these were the results of patient
lactating females were excluded. biopsies performed prior to study entry. No post-
treatment biopsies were required by the protocol.All patients provided written informed consent
before participating in the study.
Data Analysis
Study Design and Evaluations All patients were receiving open-label treatment,
and since there were no planned treatment compari-The study protocol was approved by Ethics Com-
sons, only descriptive statistics are presented for the
mittees at each of the institutions involved, and was
efficacy data. For the analysis of biochemical andperformed at 22 investigational centres in Portugal
virological response, patients with missing data
according to the latest version of the Declaration of
were included and treated as having no response.Helsinki. Patients received open-label lamivudine For the analysis of median values of liver enzymes,100mg once daily for 52 weeks. No interim analyses
only patients with data available were included.
were performed.
The screening visit was carried out within 4 Results
weeks of the baseline visit, at which study med-
ication was dispensed. After the baseline visit, pa-
Patient Accountability
tients returned every 3 months up to month 12, for
assessment. At the screening visit and at month 12 A total of 70 patients were enrolled into the study
(or after withdrawal from the study), serum was and included in the intent-to-treat population. One
assayed for HBV DNA (DNA enzyme immunoas- patient who was HBeAg negative before entering
say detection system – limit of detection: 1000 cop- the study was excluded from the statistical analysis.
ies), HBsAg and anti-HBs if HBsAg was undetect- Four patients had missing month 12 visit data and
able (Chemiluminiscencs, Diagnostic Product Cor- were treated as having no response in the intent-to
poration, Los Angeles, CA, USA), HBeAg and anti- treat analysis of virological response. Seven patients
HBe (ELFA Enzyme Linked Fluorescent Assay, withdrew before the end of the study, although three
Biomerieux Marcy, l’Etoile, France) by a single of these still returned for a follow-up assessment.
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Liver biopsies showed that at baseline 32/51 pa-
tients (62.7%) had a mild severity grading of inflam-
mation, 18/51 (35.3%) patients had moderate in-
flammation and no patients had severe inflamma-
tion. Twenty-nine patients of 52 (55.8%) had mild
fibrosis (enlarged, fibrotic portal tracts), five pa-
tients (9.6%) had moderate fibrosis (periportal or
portal-portal septa, but with intact architecture), four
patients had severe fibrosis (architectural distor-
tion), but no patients had cirrhosis.
Virological and Biochemical Response
In the intent-to-treat population, 19/69 (27.5%)
of the patients who were HBeAg positive at baseline
had a virological response, defined as loss of detect-
able HBeAg from serum with a reduction of HBV
DNA to undetectable levels (table II). Twenty-two
patients (31.9%) were HBeAg negative and 33
(47.1%) were HBV DNA negative. Figure 1 shows
the mean serum ALT and AST values (U/L)
Table I. Baseline characteristics of the 70 patients with HBeAg
positive chronic hepatitis B enrolled into the study
Age (y) 30.6 (range 16–67.2)
Sex (% male) 68.6 (48/70)
% of patients HBeAg positive 98.6 (69/70)
% of patients HBeAb positive 1.4 (1/70)
% of patients HBsAg positive 100 (69/69)
% of patients HBV DNA positive 100 (70/70)
ALT (U/L) 50 (range 30–198)
Liver biopsy – severity of inflammation: % of patients with
None 2.0 (1/51)
Mild 62.7 (32/51)
Moderate 35.3 (18/51)
Severe 0
Disease stage (fibrosis): % of patients with
None 26.9 (14/52)
Mild 55.8 (29/52)
Moderate 9.6 (5/52)
Severe 7.7 (4/52)
Cirrhosis 0
ALT = alanine aminotransferase; HBeAb = antibody to HBeAg;
HBeAg = hepatitis B e antigen; HBsAg = hepatitis B surface
antigen; HBV = hepatitis B virus.
throughout the treatment period. ALT values de-
creased steadily from a median baseline value of 89
Three patients withdrew because of adverse events U/L (range 45–390 U/L) to 27 U/L (6–550 U/L) by
and four due to ’other’ reasons. Results are 12 months. At baseline, no patients had ALT values
presented for the intent-to-treat population. within the normal range, but this increased to 61.4%
(43/70) of patients by 12 months. Similarly, median
aspartate aminotransferase (AST) levels steadily de-Baseline Characteristics
creased from a baseline value of 50 U/L (range
The baseline characteristics of the 70 patients in
the intent-to-treat population are shown in table I.
Sixty-nine percent of patients were male (48/70),
with a median age of 30.6 years (range 16–67.2
years). At baseline 69/70 (98.6%) were HBeAg pos-
itive and 69/70 (98.6%) were HBeAb negative (68/
70 were both HBeAg positive and HBeAb nega-
tive). All patients with data recorded (69/69) were
HBsAg positive and all patients were HBV DNA
positive. Sixty-nine of 70 patients had ALT values
available at baseline at which time 68 (99%) had
values between 1.3 and 10 × ULN; the median
baseline ALT value was 89 U/L (range 45–390 U/
L). Seventy percent of patients (48/69) had pre-
viously received hepatitis B therapy, i.e. interferon-
α, the standard therapy available at the time of the
study, and were non-responders.
Table II. Virological and biochemical responses at 12 months in the
intention-to-treat populationa
Percentage of patients
HBeAg negative/HBV DNA negative 27.5 (19/69b)
HBeAg negative 31.9 (22/69b)
HBV DNA negative 47.1 (33/70)
With HBeAg seroconversion 27.9 (19/68c)
HBsAg positive 100 (69/69)
With normal ALT 61.4 (43/70)
With normal AST 74.3 (52/70)
a For the virological responses, patients with missing month 12
data (n = 4) were treated as non-responders. For biochemical
responses, patients with missing month 12 data (n = 10 for
ALT and n = 13 for AST) were treated as non-responders.
b One patient was HBeAg negative at baseline.
c One patient was HBeAb positive at baseline.
ALT = alanine aminotransferase; AST = aspartate amino-
transferase; HBeAg = hepatitis B e antigen; HBsAg = hepatitis B
surface antigen; HBV = hepatitis B virus.
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30–198 U/L) to 24 U/L (range 10–300 U/L) at Hepatitis B e Antigen and Hepatitis B Surface
month 12, by which time 74.3% of patients (52/70) Antigen Seroconversion
had values within the normal range.
Of the 70 patients in the intent-to-treat popula-
tion, 68 were both HBeAg positive and HBeAb
negative at baseline. Of these, 19 (27.9%) achieved
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Fig. 1. Mean (a) alanine aminotransferase (ALT) and (b) aspartate aminotransferase (AST) levels (U/L) for hepatitis B patients during 12
months of treatment with lamivudine. Vertical lines represent mean ± SD.
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HBeAg seroconversion (HBeAg negative, HBeAb lifetime.[14] These individuals have a greatly in-
positive) by 12 months. One further patient was creased risk of severe liver disease and death from
HBeAg negative with borderline HBeAb by 12 cirrhosis or primary hepatocellular carcinoma; one
months and another patient was HBeAg negative/ retrospective analysis of chronic HBV infection in-
HBeAb negative. Of the two patients who were not dicated that 40% of adult Asian men with this dis-
HBeAg positive/HBeAb negative at baseline, one ease will die of either cirrhosis or hepatocellular
was positive for both at baseline and lost HBeAg by carcinoma.[9]
month 12 and the other was negative for both and Patients with CHB who achieve HBeAg or HB-
gained HBeAg by month 12. No patients lost HB- sAg seroconversion typically maintain states of re-
sAg during the study. duced HBV replication (or HBV elimination) for
prolonged periods, often for life, and are thought to
Safety be at reduced risk for subsequent progression of
The mean duration of treatment was 365 ± 20 their liver disease.[15-21] This is thought to be true for
days, and the drug was well tolerated during this both spontaneous and treatment-induced HBeAg
treatment period. The overall incidence of adverse seroconversions. Treatment with interferon-α can
events was 40% (28/70). Only five patients (7.1%) produce HBeAg seroconversion in approximately
experienced a serious adverse event, of which three 20–40% of treated patients.[21-23] However, patients
led to study withdrawal. The serious events were who have high levels of serum HBV DNA or mini-
pregnancy, intracranial haemorrhage, dermatitis, ab- mal evidence of inflammatory response (e.g. low
dominal pain and elevated creatinine serum ALT levels) appear to have lower response
phosphokinase; the latter two events were consid- rates to interferon therapy.[23] Furthermore, interfer-
ered by the investigator to be attributable to on use in patients with advanced liver disease re-
lamivudine treatment. In total, ten patients (14.3%) quires particular caution.[24-26] Hence, although in-
experienced adverse events considered by the inves- terferon has been an important first step in hepatitis
tigator to be drug-related. Table III shows the pro- B therapy, widespread clinical acceptance of in-
portion of patients experiencing the most common terferon treatment has been limited by its inconve-
adverse events (≥5%); these were abdominal dis- nience (parenteral dosing), side effect profile, costs
comfort and pain, headaches, malaise/fatigue, viral and lack of response in the majority of patients.
respiratory infections and hair loss/alopecia. Lamivudine is the first oral antiviral therapy ap-
ALT values >10 × ULN were noted in five pa- proved for the treatment of CHB. It is a nucleoside
tients (7%) at month 2 and then in one patient at analogue that rapidly and profoundly suppresses
month 8 (1%) and one patient at month 12 (2%). HBV replication through inhibition of viral DNA
synthesis. The efficacy and safety of lamivudine inDiscussion CHB has been extensively studied in the Far East,
the US and Europe and shows that lamivudine pro-In chronic HBV carriers, only 1–2% will lose
vides a rapid and consistent suppression of serumHBsAg per year, thus many remain infected for their
HBV levels with normalisation of ALT.[10,11,27,28]
Through its viral inhibition, lamivudine treatment
results in enhanced seroconversion and reduced
hepatic necroinflammatory activity and therefore
appears to slow the progression of fibrosis in pa-
tients with ongoing viral replication and compensat-
ed liver disease.[10-13]
Newer pharmacotherapeutic agents are being de-
veloped and hold promise for the treatment of HBV
Table III. Proportion of patients experiencing the most common
adverse events (≥5%)
Adverse event No. of patients with
adverse events (%)
Abdominal discomfort and pain 4 (5.7)
Headaches 4 (5.7)
Malaise and fatigue 4 (5.7)
Viral respiratory infections 5 (7.1)
Hair loss and alopecia 4 (5.7)
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precore/core mutant.[29] Adefovir dipivoxil is a re- of therapy, where most were mild and not consid-
cently approved nucleotide analogue for the treat- ered to be related to lamivudine.[10-12,27,28] Analyses
ment of chronic hepatitis B infection.[30,31] of the subset of adverse events considered to be
possibly or probably related to the study drug or of
unknown relationship revealed similar frequenciesConclusion
of such events for patients treated with lamivudine
In this study of 70 Portuguese patients, HBV or placebo. The incidence of adverse events in this
DNA responses to lamivudine therapy were similar Portuguese study was in keeping with these findings
to those reported elsewhere, with 47% (33/70) of and revealed a similar profile of most commonly
patients having suppression of HBV DNA to unde- reported adverse events.
tectable levels after 52 weeks of lamivudine therapy. In conclusion, this Portuguese study corroborated
Improvements in ALT were also observed, with the findings of earlier studies, showing that
median values approaching the normal range after 6 lamivudine treatment in patients with HBeAg posi-
months. Sixty-one percent of patients had ALT val- tive CHB is well tolerated and results in both viro-
ues within the normal range after 52 weeks of ther- logical and biochemical improvements, with
apy, reflecting rates reported in other studies.[10] HBeAg seroconversion achieved in one third of
Such normalisation of serum ALT is indicative of patients.
reduced liver damage, since serum ALT concentra-
tions are thought to correlate reasonably well with Acknowledgements
liver disease measured histologically.[32] Funding for the study (protocol no. NUCPT01) was pro-
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